Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14724231 | 0.80 | MEN1 (0.34) | BRAFCNR1CNR2CHRNB4CHRNA3 | |
| SCHEMBL9610944 | 0.79 | MEN1 (0.44) | EPHX2MAPK14 | |
| SCHEMBL9891486 | 0.79 | ALDH1A1 (0.35) | BRAFCNR1CNR2MAPK14 | |
| SCHEMBL1013430 | 0.79 | BRAF (0.32) | BRAFCNR1CNR2 | |
| SCHEMBL14723927 | 0.76 | ALDH1A1 (0.36) | BRAFCNR1CNR2EPHX2 | |
| SCHEMBL19480811 | 0.76 | CHRNA1 (0.32) | EPHX2CHRNA1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3709322 | 0.73 | SIRT6 (0.36) | BRAFCNR1CNR2MAPK13MAPK12 | |
| SCHEMBL14394656 | 0.73 | L3MBTL1 (0.33) | EPHX2CHRNA1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21671072 | 0.73 | CHRNA1 (0.31) | CHRNA1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9892787 | 0.72 | EGFR (0.52) | BRAFEPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | BRAF 4446/4885CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.